Search results
Results from the WOW.Com Content Network
Calcitonin. Calcitonin is a 32 amino acid peptide hormone secreted by parafollicular cells (also known as C cells) of the thyroid (or endostyle) in humans and other chordates [5] in the ultimopharyngeal body. [6] It acts to reduce blood calcium (Ca 2+), opposing the effects of parathyroid hormone (PTH). [7]
Domains. InterPro. Calcitonin gene-related peptide (CGRP) is a member of the calcitonin family of peptides consisting of calcitonin, amylin, adrenomedullin, adrenomedullin 2 (intermedin) and calcitonin‑receptor‑stimulating peptide. Calcitonin is mainly produced by thyroid C cells whilst CGRP is secreted and stored in the nervous system. [1]
Atogepant, sold under the brand name Qulipta among others, is a medication used to prevent migraines. [4][5] It is a gepant, an orally active calcitonin gene-related peptide receptor antagonist. [4][7] The most common side effects include nausea, constipation, tiredness, somnolence (sleepiness), decreased appetite, and decreased weight.
Ubrogepant is a small-molecule calcitonin gene-related peptide receptor antagonist. [7][8] It is the first drug in this class approved for the acute treatment of migraine. The most common side effects are nausea, tiredness and dry mouth. [6] Ubrogepant is contraindicated for co-administration with strong CYP3A4 inhibitors.
[6] [3] Other side effects may include hypersensitivity reactions. [6] Galcanezumab was developed by Eli Lilly. [8] It was approved for medical use in the United States and in the European Union in 2018, [9] [10] [3] becoming the third calcitonin gene-related peptide (CGRP) inhibitor to be approved by the US Food and Drug Administration (FDA). [11]
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drugs that act as antagonists of the calcitonin gene-related peptide receptor (CGRPR). [1] Several monoclonal antibodies that bind to the CGRP receptor or peptide have been approved for prevention of migraine. [2] Nerve activation triggers the release of CGRP and other ...
Cinacalcet is a drug that acts as a calcimimetic [4][5] (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. The calcium-sensing receptors on the surface of the chief cell of the parathyroid gland is the principal negative regulator of ...